Kallikrein 8/Neuropsin Antibody (369910) [Alexa Fluor® 488]

• Reactivity: Hu
• Applications: IP, B/N
• Clone: 369910
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 488

Kallikrein 8/Neuropsin Antibody (369910) [Alexa Fluor® 488] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Kallikrein 8/Neuropsin
  Gln29-Gly260 (predicted)
  Accession # O60259
• Specificity: Detects human Kallikrein 8/Neuropsin in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) UPA‑1, rhKallikrein 1, 2, 3, 4, 5, 7, 9, 10, 11, 12, 13, 14, 15, rhKallikrein B1, rhHGFA, rhFactor&
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation
  • Neutralization

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Kallikrein 8/Neuropsin Antibody (369910) [Alexa Fluor® 488]

• EC 3.4.21
• EC 3.4.21.118
• hK8
• HNP
• kallikrein 8 (neuropsin/ovasin)
• Kallikrein 8
• kallikrein-related peptidase 8
• KLK8 protein type 1
• KLK8 protein type 2
• KLK8
• neuropsin type 1
• neuropsin type 2
• Neuropsin
• NP
• NRPN
• Ovasin
• PRSS19
• PRSS19kallikrein-8
• Serine protease 19
• Serine protease TADG-14
• TADG14neuropsin
• Tumor-associated differentially expressed gene 14 protein

Background

Kallikrein 8 (KLK8), also known as neuropsin or ovasin, is a member of the human tissue kallikrein family (1). Two alternatively spliced forms exist, resulting in 260 (isoform 1) and 305 (isoform 2) amino acid (aa) sequences, respectively (2). Isoform 1 consists of a signal peptide (residues 1 to 28), a short pro peptide (aa 29‑32) and the mature chain (aa 33-260). Isoform 2 is identical to isoform 1, except that a 45 aa segment is inserted in isoform 2 between aa 23 and 24 in isoform 1. Isoform 1 is predominantly expressed in pancreas whereas isoform 2 is preferentially expressed in adult brain and hippocampus, although both forms are expressed in fetal brain and placenta in comparable levels. The brain function of KLK8 seems evident in neuropsin knockout mice that showed abnormalities of synapses and neurons and predisposation to global seizure activity (3, 4). KLK8 is a novel marker for ovarian and cervical cancer carcinomas (5, 6). Recombinant human KLK8, after being activated by lysyl endopeptidase, can cleave fibronectin and several small peptide substrates (7, 8).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • O60259()